Skip to main content
. 2014 Mar 5;7(3):311–338. doi: 10.3390/ph7030311

Table 2.

Radiolabeled cetuximab conjugates studied in tumor-bearing mice.

Radionuclide Chelator Tumor type Application Tumor uptake Tumor/muscle ratio Liver uptake Reference
(%ID/g, 24 h post-injection)
64Cu DOTA h GB i.v. 12.5 5 15 [59]
h PC 11 4.5 6 (rat)
h CRC ~5 2
m CRC 10 4
h M
64Cu DOTA h CC i.v. 14 3.5 16 [60]
64Cu DOTA PC-3 i.v. 15 15 17 [151]
64Cu DOTA A431 i.v. 18.5 8.5 13 [61]
h M 2.6 1.3 10
64Cu DOTA h HNSCC (UMSCC22B) i.v. 19 6 11 [117] a
64Cu DOTA h HNSCC (UMSCC1) i.v. 6 2.5 13 [117] a
64Cu NOTA m BC i.v. 4 4 19 [155]
64Cu NOTA m BC i.v. 20 10 19 [54]
66Ga NOTA h BC i.v. 4 5 6 [72] b
86Y DTPA h CRC i.v. 21 11 10 [83]
88Y DTPA A431 i.p. 21 14 11 [74]
88Y DOTA A431 i.p. 17 11 10 [74]
89Zr Df h GB i.v. 15 15 10-12 [141]
h CRC 10 10
A431 8 8
h BC 3 3
89Zr Df A431 i.v. 3.5c 10d 11c [142]
89Zr Df A431 i.p. 21 17 10 [74]
89Zr Df A431 i.v. 15 8 9 [139]
89Zr + Df A431 i.v. 22 19 20 [156]
89Zr + ½ dye e Df 20 19 22
89Zr + 1 dye Df 20 19 25
89Zr + 2 dye Df 13 16 40
99mTc EC h BC i.v. 0.3 8.5 0.6 [91]
86Y DTPA h CRC i.v. 21 11 10 [83]
88Y DTPA A431 i.p. 21 14 11 [74]
88Y DOTA A431 i.p. 17 11 10 [74]
90Y DOTA normal rats i.v. 2 [157]
177Lu DOTA A431 i.p. 18 12 13 [109]
177Lu DOTA A431 i.p. 17.5 12 8-13 [74]
177Lu DTPA A431 i.p. 17.5 12 7 [74]
111In DTPA A431 i.v. 11 29 47 [158] f
DTPA-PEG A431 8.7 13 25
111In DTPA h OC i.v. 8.8 11 4 [95] f
111In DTPA h CRC i.v. 28/24g 28/24g 9/16g [85]
h PC 16 16 6
h PancC 10 10 10
h OC 13 13 10
h M 3 3 9
111In DTPA h HNSCC i.v. 20 14 11 [108]
111In DTPA h BC i.v. 18/40f 13 11/15f [135]
111In DTPA h HNSCC (FaDu) i.v. 27 13 8 [159]
125I h HNSCC i.v. 11 8 7 [108]
125I A431 i.p. 8.4 5.6 4 [109]
125I A431 i.p. 8 5 4 [74]

Df desferrioxamine chelating unit; EC ethylenedicysteine; h human; m murine; GB glioblastoma; CRC colorectal carcinoma; A431 human epidermoid carcinoma; BC breast carcinoma; PC prostate carcinoma; CRC colorectal carcinoma; CC cervical cancer; M melanoma (MDA-MB-435); HNSCC head and neck squamous cell carcinoma; UMSCC22B cells of the lymph node the oropharynx; UMSCC1 cells of the oral cavity; OC ovarian carcinoma; PancC pancreas carcinoma; FaDu hypopharyngeal carcinoma cell line; a 20 h after radiotracer injection; b 36 h after radiotracer injection; c %ID/mL tumor PET analysis; d tumor to background (pelvic); e different equivalents of the dye IRDye800CW; f 48 h after radiotracer injection; g value from two different types of h CRC xenografts.